Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 17, 2026Molecular Nutrition & Food Research

Modulation of Microbiota‐Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation

View Full Paper
Ask AI
Bookmark
Share

Authors

PJPaige E. JamiesonIGInah GuNRNicholas J. Reichart

Discussion

Loading...

Member takes

Overview

Randomized trial shows symptom improvement in Crohn's disease with xanthohumol, suggesting beneficial gut modulation.

Key Points

  • To explore the effects of xanthohumol on the gut environment and symptoms in individuals with Crohn's disease.
  • Randomized, placebo-controlled trial (NCT4590508)
  • 19 participants with clinically active Crohn's disease
  • Xanthohumol 24 mg/day or placebo for 8 weeks with clinical assessments bi-weekly.
  • Significant reduction in secondary bile acids in XN-treated individuals
  • Increased IL-10 levels correlated with improved Crohn's disease activity index (CDAI) scores
  • CDAI scores improved in participants receiving xanthohumol.

Cite This Study

Jamieson et al. (2026) studied this question.

synapsesocial.com/papers/6a095ba67880e6d24efe1733https://doi.org/10.1002/mnfr.70501
View Full Paper
Ask AI
Bookmark
Share